European Innovation Council · Running
VANTAGE Vascularized Next-Generation Tumor-on-Chip for ADC Global Evaluation
- Coordinator
- Universitaet Bern, Switzerland
- Runs
- 1 September 2026 to 31 May 2027
- Status
- Running
- EU funding
- €300k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101327116
What the project is doing
In the project's own words, from its summary on CORDIS.
Objectives: The project aims to industrialize a human vascularized tumor-on-chip (VANTAGE) to bridge the ""predictive gap"" in Antibody-Drug Conjugate (ADC) development. Primary goals include: (1) Quantifying the ""total spectrum"" of ADC efficacy, from primary tumor regression to the inhibition of micrometastatic seeds
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitaet Bern | Bern | Switzerland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI